AOTMiT: Transparency Council on AD, SLA and POCHP, among others

1. evaluation of drugs under drug programs

1.1 Prepare a position on drug evaluation:

• Imfinzi (durvalumabum)
• Lynparza (olaparibum)
  under drug program B.148: "Treatment of patients with endometrial cancer (ICD-10: C54)."

1.2 Prepare a position paper on drug evaluation:

• Keytruda (pembrolizumab)
  under drug program B.148: "Treatment of patients with endometrial cancer (ICD-10: C54)."

1.3 Prepare a position paper on drug evaluation:

• Cibinqo (abrocitinibum)
  under drug program B.124: "Treatment of patients with atopic dermatitis (ICD-10: L20)."

2. drug reimbursement approvals - assessment of reasonableness

2.1 Edarabid (edaravone) - indication: amyotrophic lateral sclerosis.

2.2 Synacthen; Synacthen Depot (tetracosactide) - indications:

• drug-resistant epilepsy,
• West syndrome,
• Lennox-Gastaut syndrome,
• Kinsbourne syndrome,
• Landau-Kleffner syndrome.

3 Opinion on health policy programs

3.1 Prevention of Chronic Obstructive Pulmonary Disease.

3.2 "Program for prevention and early detection of depression in the youth population in the Municipality of Białobrzegi for 2026-2028".

3.3 "Program for prevention and early detection of hip dysplasia in Myslenice County for 2026-2030".

3.4 "Program for dissemination of first aid skills in Myslenice County for 2026-2030".

4. opinion for active substances - reimbursement outside the SmPC or for specific indications

4.1 Leflunomide - indication: juvenile idiopathic arthritis - polyarticular form after failure or intolerance of methotrexate.

4.2 Acidum folicum - indication: psoriasis in patients treated with methotrexate.

4.3 Amiloridum + hydrochlorothiazidum - indication: renal uremia.

4.4 Prednisone - indications:

• Obstructive pulmonary diseases (outside the scope of the SmPC),
• Autoimmune diseases (outside the scope of the SmPC),
• Post-transplant condition (organ, limb, tissue, cells, marrow).

4.5 Fenoteroli hydrobromidum + ipratropii bromidum - indications:

• cystic fibrosis,
• bronchopulmonary dysplasia,
• ciliary dyskinesia.

4.6 Ipratropii bromidum - indications:

• cystic fibrosis,
• bronchopulmonary dysplasia,
• ciliary dyskinesia.

Source: AOTMiT